Purification, characterization, and N‐glycosylation of recombinant butyrylcholinesterase from transgenic rice cell suspension cultures
Abstract
Recombinant butyrylcholinesterase produced in a metabolically regulated transgenic rice cell culture (rrBChE) was purified to produce a highly pure (95%), active form of enzyme. The developed downstream process uses common manufacturing friendly operations including tangential flow filtration, anion‐exchange chromatography, and affinity chromatography to obtain a process recovery of 42% active rrBChE. The purified rrBChE was then characterized to confirm its comparability to the native human form of the molecule (hBChE). The recombinant and native enzyme demonstrated comparable enzymatic behavior and had an identical amino acid sequence. However, rrBChE differs in that it contains plant‐type complex N‐glycans, including an α‐1,3 linked core fucose, and a β‐1,2 xylose, and lacking a terminal sialic acid. Despite this difference, rrBChE is demonstrated to be an effective stoichiometric bioscavenger for five different organophosphorous nerve agents in vitro. Together, the efficient downstream processing scheme and functionality of rrBChE confirm its promise as a cost‐effective alternative to hBChE for prophylactic and therapeutic use.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Feb 27, 2018
- Source ID
- 10.1002/bit.26557
Entities
People
- C Linn Cadieux
- Carlito B. Lebrilla
- Douglas M. Cerasoli
- Jasmine M. Corbin
- Kalimuthu Karuppanan
- Karen A McDonald
- Muchena J. Kailemia
- Raymond L. Rodriguez
- Salem Alkanaimsh
- Somen Nandi
Organizations
- Defense Threat Reduction Agency
- National Institute of General Medical Sciences
- United States Army Medical Research Institute of Chemical Defense
- University of California, Davis